← Back

Wire · operational-macro

Elticertinib Receives FDA Fast Track Designation in EGFR Exon 20–Mutated NSCLC

Published

18 November 2026

Topic

operational-macro

◆ Sectors

Drug Discovery

◆ Geography

United States

◆ Source

Read at onclive.com →

◆ Verified

Fusion42 · 18 November 2026 · Fusion42 review

Elticertinib has been granted FDA Fast Track designation for treating NSCLC with EGFR exon 20 mutations, potentially expediting its development and review.

This Wire brief sits within Fusion42's coverage of Drug Discovery.

◆ ◆ The Wire takeaway

You need to prepare for quicker market entry and tighter regulatory timelines as FDA Fast Track status opens earlier access for your EGFR exon 20 NSCLC therapies.

◆ Coverage

1 source · 18 Nov 2026

◆ Related on Wire

◆ Topics

Drug Discoveryfdafast-tracknsclcegfr-mutationoncology